Key result
Oxaliplatin-treated patients with Lhermitte's phenomenon showed a greater reduction in sensory nerve refractoriness than those without the phenomenon.
Why the study?
What is the pathophysiology underlying Lhermitte's phenomenon in oxaliplatin-treated patients?
Observational
What is the pathophysiology underlying Lhermitte's phenomenon in oxaliplatin-treated patients?
Lhermitte's phenomenon in oxaliplatin-treated patients represents a severe presentation of generalized nerve dysfunction rather than structural spinal abnormalities.
Answers are grounded in this paper and cite their sources.
Suggests Lhermitte's signals broader oxaliplatin neuropathy; leaves open excitability testing for risk stratification.
OBJECTIVES: Lhermitte's phenomenon, characterized by 'electric-shock' sensations precipitated by neck flexion, may develop during oxaliplatin treatment. Limited cases have been described previously and the pathophysiology underlying Lhermitte's phenomenon in oxaliplatin-treated patients has not been established. METHODS: Patients who developed Lhermitte's phenomenon during oxaliplatin therapy were investigated by neurological examination, neurotoxicity grading and conventional nerve conduction studies (NCS). Structural (magnetic resonance imaging) and functional (somatosensory evoked potentials) spinal assessment was also undertaken. Sensory nerve excitability recordings were performed longitudinally across treatment to investigate ion channel function. RESULTS: Five oxaliplatin-treated patients reported Lhermitte's phenomenon, with a mean cumulative dose of 861 +/- 84 mg/m(2) oxaliplatin (range 574-1,100 mg/m(2)). NCS revealed severe sensory neuropathy in all patients. There was no evidence of structural or functional spinal cord damage. Nerve excitability studies revealed progressive alterations in sensory excitability throughout treatment, consistent with oxaliplatin-induced nerve dysfunction. In patients with Lhermitte's phenomenon, refractoriness was reduced to -14.4% (confidence interval, CI: -20.5 to -8.4%) by late treatment, a significantly greater reduction than in oxaliplatin-treated patients who did not develop Lhermitte's phenomenon (-2.7%; CI: -7.6 to 2.2; p = 0.013). CONCLUSIONS: Lhermitte's phenomenon represents a severe presentation of oxaliplatin-induced neurotoxicity, associated with generalized nerve dysfunction in the absence of structural spinal abnormalities.
No takes yet. Share an insight, caveat, or question.
Park et al. (2009) conducted an observational in Oxaliplatin-induced neurotoxicity. Lhermitte's phenomenon development vs. Oxaliplatin-treated patients without Lhermitte's phenomenon was evaluated on Sensory nerve refractoriness by late treatment (p=0.013). Oxaliplatin-treated patients with Lhermitte's phenomenon showed a greater reduction in sensory nerve refractoriness than those without the phenomenon.
Synapse has enriched 10 related papers. Consider them for comparative context: